Efficacy and tolerability of PTK787/ZK 222584 in a phase II study of post-transplant maintenance therapy in patients with multiple myeloma following high-dose chemotherapy and autologous stem cell transplant.
Vij
Ravi
R
Ansstas
George
G
Mosley
James C
JC
Bryant
George
G
Hassan
Anjum
A
Amador-Ortiz
Catalina
C
Procknow
Elizabeth
E
D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009101:Multiple Myeloma / Q000473:pathology / Q000628:therapy*; D010793:Phthalazines / Q000627:therapeutic use*; D011446:Prospective Studies; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D012074:Remission Induction; D033581:Stem Cell Transplantation; D015996:Survival Rate; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D010793:Phthalazines; D047428:Protein Kinase Inhibitors; D011725:Pyridines; C404768:vatalanib